Chemotherapy comparison for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial compares two different chemotherapy combinations given before radiation for nasopharyngeal cancer. It is for patients with advanced but not metastatic disease who are in good overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have a specific type of nasopharyngeal cancer (called differentiated or undifferentiated non-keratinizing carcinoma)
- Your cancer is at a certain stage (T4 with any N, or N2-3 with any T)
- You are in good general health (able to do light work or fully active)
- Your blood counts and kidney/liver function are within normal limits
- You agree to use effective birth control if you or your partner could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding chemotherapy before the usual radiation and chemotherapy treatment can improve outcomes for people with a certain type of nasopharyngeal cancer that has higher risk features. It aims to see if the extra treatment helps control the cancer better.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests a new combination of three drugs (TPC, apatinib, and camrelizumab) against the standard two-drug regimen (GP plus camrelizumab) for people with high-risk nasopharyngeal carcinoma that has spread to neck lymph nodes. The goal is to see if the three-drug combination works better and is safe.
This trial compares two treatment plans for newly diagnosed, operable nasopharyngeal cancer: adding surgery plus targeted chemoradiation versus standard chemoradiation alone. It aims to see whether the surgery-based plan improves control of the cancer and related outcomes.
This trial tests a new combination of chemotherapy drugs (GP) plus an immunotherapy drug (adebrelimab) before standard treatment for nasopharyngeal cancer. It aims to see if this combination works better than chemotherapy alone for shrinking tumors.
This trial compares two treatment options for people with nasopharyngeal cancer that did not respond well to initial chemotherapy. One option is to switch to a different chemotherapy regimen, the other is to go straight to radiation therapy. The study aims to see which approach is more effective in this situation.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.